Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-DC
- Development stage
- Unknown
- Lead developer
- Peking University Shenzhen Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-DC (Peking University Shenzhen Hospital) is an investigational autologous cell therapy consisting of dendritic cells (DCs) genetically modified to express a chimeric antigen receptor (CAR). Developed by Peking University Shenzhen Hospital, this therapy is being evaluated for the treatment of advanced solid tumors. Unlike traditional CAR-T therapies that use T cells as the effector, CAR-DC leverages the natural antigen-presenting and phagocytic functions of dendritic cells. The CAR constructs are designed to target specific tumor-associated antigens, including EphA2, CLDN18.2, Trop2, HER2, GCC, GPC3, and CEA, depending on the patient's tumor profile. The goal of the treatment is to enhance the immune system's ability to recognize and eliminate malignant cells through both direct action and the stimulation of endogenous anti-tumor immunity.
- Other names
- chimeric antigen receptor-modified dendritic cellCAR-modified dendritic cell
02
Targets
CD40 (Cluster of differentiation 40 receptor)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)Claudin 18.2EPHA2 (Ephrin type-A receptor 2)GUCY2C (Guanylate cyclase C receptor)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)GPC3 (Glypican-3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on CAR-DC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-DC.